Topics

About this talk

Our next Guest Lecture, from Professor Naveed Sattar, Professor of Cardiometabolic Medicine, University of Glasgow will explore the potential for intentional weight loss to act as a disease-modifying strategy across a wide range of obesity-related conditions. Drawing together four complementary sources of evidence — epidemiology, genetic analyses including Mendelian randomisation, observational studies of weight change, and randomised clinical trials — Professor Sattar will demonstrate how these different approaches can be combined to strengthen our understanding of causality and the impact of weight loss on disease. Chaired by Susan Jebb, Professor of Diet and Population Health, Nuffield Department of Primary Care Health Sciences, the session will highlight evidence for intentional weight loss as a disease-modifying intervention in conditions including type 2 diabetes, obstructive sleep apnoea, MASLD/MASH, HFpEF, hypertension and osteoarthritis, as well as examining the evolving evidence in atherosclerotic cardiovascular disease. The lecture will also look ahead to the important questions that remain unanswered. Available evidence suggests excess adiposity is likely to play a causal role in conditions ranging from atrial fibrillation, gout and GORD to psoriasis, depression, asthma, COPD and rheumatoid arthritis, yet further weight-loss trials using different interventions are still needed. With licensed therapies such as semaglutide and tirzepatide now achieving substantial weight loss, and several newer therapies in late-stage development, the evidence gaps point to important priorities for the next generation of clinical trials. Join this session to explore what the evidence tells us today - and the critical questions future weight-loss trials need to answer.

→ More information & booking (opens in new tab)